公开(公告)号：US11174240B2

公开(公告)日：2021-11-16

申请号：US16605380

申请日：2018-04-20

Applicant: Aptabio Therapeutics Inc.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee

IPC: C07D401/04

Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.

公开(公告)号：US20210122726A1

公开(公告)日：2021-04-29

申请号：US16605380

申请日：2018-04-20

Applicant: Aptabio Therapeutics Inc.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee

IPC: C07D401/04

Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.

公开(公告)号：US10966969B2

公开(公告)日：2021-04-06

申请号：US16481307

申请日：2018-09-14

Applicant: APTABIO THERAPEUTICS INC.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee ,  Yun Soo Bae

IPC: A61K31/4439 ,  A61P1/16

Abstract: Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.